Skip to main content


Table 4 Worst case scenario, with all inputs biased against the empiric MIC vs. FLU strategy

From: Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation

Candidemia as % BSI 0.48
CK/CG as % candidemia 0.132
Candidemia attributable mortality 0.2
Candidemia mortality reduction if treated appropriately 0.35
Total duration of treatment with appropriate treatment (days) 14
Time to C&S results (days) 4
Time initial treatment following C&S results (days) 10
Time treatment following switch for C&S results (days) 14
Cost per day FLU ($) $10
Cost per extra 400 mg loading day 1 in FLU gr $10
Cost per day MIC ($) $120
Age 80
Life expectancy 13
Relative risk of death 0.59
Time-trade off utility (QALY adjustment) 0.44
Age-specific annual healthcare costs in 2001 $US* $20,558
Annual discount rate 0%
Incremental lifetime cost per QALY $72,318
  1. * All costs inflated to 2008 $US using medical component of the consumer price index.
  2. BSI = bloodstream infection; CG = Candida glabrata; CK = Candida krusei; C&S = culture and sensitivity; FLU = fluconazole; MIC = micafungin; QALY = quality-adjusted life year.